Available Brands
Did you find this information helpful?
Author Details
Written By
P. Thirumal Reddy
B. Pharm
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 17 Sep 2024 | 07:27 AM (IST)
Want to know more?
Read Our Editorial Policy
Quick Summary
REPAGLINIDE
Last updated on 17 Sep 2024 | 07:27 AM (IST)
REPAGLINIDE
Background and Date of approval REPAGLINIDE
Repaglinide was initially approved by the United States Food and Drug Administration (FDA) in December 1997.
A 2003 study evaluated the safety and effectiveness of repaglinide in patients with type 2 diabetes. The study found that repaglinide effectively lowered HbA1c levels and improved glycemic control while presenting a relatively low risk of hypoglycemia. The study also demonstrated that repaglinide is safe for use in patients with varying degrees of renal impairment.
Uses of REPAGLINIDE
Repaglinide is indicated for adults with type 2 diabetes mellitus when diet, weight reduction, and exercise no longer control their hyperglycemia satisfactorily. It is recommended for adults with type 2 diabetes mellitus who show no improvements when treated with metformin alone.
How is REPAGLINIDE administered?
You should take repaglinide tablets orally before each meal, anytime from 30 minutes before a meal to just before the meal. If you skip a meal, skip the dose of repaglinide. If you add an extra meal, take an extra dose of repaglinide. Your doctor may gradually adjust your dose based on your response to the medication.
Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any parts you do not understand. Take repaglinide exactly as directed—do not take more or less than instructed or more frequently than advised by the package label or your doctor.
Continue taking repaglinide even if you feel well, and do not stop taking it without consulting your doctor.
Side Effects of REPAGLINIDE
Common side effects of repaglinide include:
- Low blood sugar
- Weight gain
Serious side effects of repaglinide are:
- Allergic reactions
- Liver problems
- Rare cases of anaemia, thrombocytopenia, or leukopenia.
Warnings
Repaglinide can cause severe low blood sugar, particularly if patients skip meals or increase their exercise. Use Repaglinide with caution in individuals with liver issues, as the liver metabolises the drug and dose adjustments may be necessary. Be aware that some medications can affect the effectiveness of Repaglinide or heighten the risk of hypoglycemia. During pregnancy, use Repaglinide only if required, and consult a doctor if breastfeeding.
Precautions
- Monitor blood glucose levels: Regularly check blood glucose levels to avoid hypoglycemia.
- Adjust dosage in hepatic impairment: Adjust the dose for patients with liver dysfunction, as the liver metabolises Repaglinide.
- Consider drug interactions: Be cautious with drugs that can affect Repaglinide's effectiveness or increase the risk of low blood sugar.
- Use with caution in renal impairment: Monitor and adjust the dose for patients with kidney problems.
- Avoid in pregnancy unless necessary: Use Repaglinide during pregnancy only if the benefits outweigh the risks and consult healthcare professionals.
- Monitor for allergic reactions: Watch for signs of serious allergic reactions, such as rash, itching, or swelling.
Word of Advice
Inform your doctor of any liver or kidney issues and monitor your blood glucose levels regularly to prevent hypoglycemia. Report any symptoms of low blood sugar and inform your provider of all other medications you take to avoid interactions. Use Repaglinide during pregnancy only if essential, and watch for allergic reactions, reporting any issues immediately.
Frequently Asked Questions
Q1.
What kind of drug is repaglinide?
Repaglinide is an oral antidiabetic medication used to manage type 2 diabetes. It belongs to the class of drugs known as meglitinides. It works by stimulating the pancreas to release more insulin in response to elevated blood glucose levels. Repaglinide helps to lower blood sugar levels, especially around meal times.
Q2.
Is repaglinide a sulfonylurea?
No, repaglinide is not a sulfonylurea. It is a meglitinide, which is a different class of oral antidiabetic medications. While both meglitinides and sulfonylureas work by stimulating insulin release from the pancreas, they have different mechanisms of action and pharmacological properties. Meglitinides, like repaglinide, act more rapidly and have a shorter duration of action compared to sulfonylureas.
Q3.
When is the best time to take repaglinide?
Take repaglinide tablets by mouth before meals, anywhere from 30 minutes to just before eating. If you skip a meal, skip that dose of repaglinide. If you add an extra meal, take an additional dose of repaglinide.
Q4.
Is repaglinide safe for kidneys?
Repaglinide is generally safe for people with kidney issues, but it requires careful monitoring and dosage adjustments. Your healthcare provider will ensure safety by monitoring your kidney function and adjusting the dose as needed.
Q5.
Can repaglinide be taken without food?
No, repaglinide should not be taken without food. It is designed to be taken just before meals to manage postprandial blood glucose levels. Taking it without food increases the risk of hypoglycemia. If you miss a meal, you should skip the dose of repaglinide.
Q6.
What foods to avoid with repaglinide?
Avoid high-sugar and high-carbohydrate foods like sugary snacks and refined grains, as they can cause blood sugar spikes. Limit excessive alcohol consumption and high-fat foods to prevent complications. Be cautious with grapefruit, as it may interfere with medication metabolism. Consult your healthcare provider for personalised dietary advice.
References
- Christoph Hasslacher, for the Multinational Repaglinide Renal Study Group; Safety and Efficacy of Repaglinide in Type 2 Diabetic Patients With and Without Impaired Renal Function. Diabetes Care 1 March 2003; 26 (3): 886–891.https://doi.org/10.2337/diacare.26.3.886
- https://www.ema.europa.eu/en/documents/product-information/prandin-epar-product-information_en.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020741s041s042lbl.pdf
Disclaimer
The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.
